{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:56:35Z","timestamp":1791467795521,"version":"4.3.4"},"reference-count":61,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"National Cancer Center Research and Development Funds, Japan","award":["2023-J-03"],"award-info":[{"award-number":["2023-J-03"]}]},{"name":"Japan Agency for the National Cancer Center Research and Development Fund","award":["25ck0106025h0001"],"award-info":[{"award-number":["25ck0106025h0001"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Head and neck squamous cell carcinoma (HNSCC) often requires invasive multimodal therapy, including surgery, radiotherapy, and chemotherapy. Although these interventions have improved treatment outcomes, patients frequently experience long-term functional impairment and treatment-related morbidity. Consequently, clinical research has shifted toward treatment de-escalation, a paradigm aimed at preserving quality of life while maintaining oncologic control. This review summarizes the current evidence from prospective clinical trials on de-escalation strategies for HNSCC of the oropharynx, hypopharynx, larynx, and oral cavity, with a focus on radiotherapy-based approaches. Investigators have evaluated several de-escalation strategies, including total radiation dose reduction in definitive chemoradiotherapy, modification or omission of concurrent systemic therapy, de-intensification of prophylactic nodal irradiation, response-adapted treatment de-intensification, and minimally invasive approaches such as transoral surgery with risk-adapted postoperative therapy. These strategies target favorable-risk populations, particularly patients with human papillomavirus-associated oropharyngeal cancer. Although numerous phase II studies have reported encouraging clinical outcomes and acceptable toxicity profiles, definitive evidence supporting the safety and efficacy of de-escalation strategies remains unestablished in large-scale phase III trials. Unwarranted de-escalation for HNSCC should be avoided, particularly for medically fit patients, and promising strategies require validation in phase III trials before routine clinical adoption. Future challenges include prospective validation through clinical trials and the integration of predictive biomarkers to balance the delicate trade-off between toxicity reduction and oncologic safety.<\/jats:p>","DOI":"10.1093\/jjco\/hyag096","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T11:49:40Z","timestamp":1780055380000},"page":"1167-1181","source":"Crossref","is-referenced-by-count":0,"title":["Current status and future perspectives of treatment de-escalation in localized head and neck cancer"],"prefix":"10.1093","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8904-8825","authenticated-orcid":false,"given":"Shinya","family":"Hiraoka","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University , 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto , 606-8507,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7075-8488","authenticated-orcid":false,"given":"Takeshi","family":"Kodaira","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Aichi Cancer Center Hospital , 1-1 Kanokoden, Chikusa-ku, Nagoya , 464-6111,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2524-8283","authenticated-orcid":false,"given":"Nobuhiro","family":"Hanai","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, Aichi Cancer Center Hospital , 1-1 Kanokoden, Chikusa-ku, Nagoya ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8021-6116","authenticated-orcid":false,"given":"Naomi","family":"Kiyota","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, Cancer Center, Kobe University Hospital , 7-5-2 Kusunoki-cho, Chuo-ku, Kobe , 650-0017,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"2026100809072055800_ref1","volume-title":"Head and neck cancers. Version 1.2026. Plymouth meeting: National Comprehensive Cancer Network","author":"National Comprehensive Cancer Network"},{"key":"2026100809072055800_ref2","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1097\/00002820-200511000-00004","article-title":"Eating problems and weight loss for patients with head and neck cancer: a chart review from diagnosis until one year after treatment","volume":"28","author":"Larsson","year":"2005","journal-title":"Cancer Nurs"},{"key":"2026100809072055800_ref3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.radonc.2022.03.020","article-title":"Early non-cancer mortality risk prediction after curative-intent radiotherapy or chemoradiotherapy for head and neck squamous cell carcinoma","volume":"171","author":"Jensen","year":"2022","journal-title":"Radiother Oncol"},{"key":"2026100809072055800_ref4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/jrr\/rrad087","article-title":"Long-term outcomes of stimulated salivary flow and xerostomia after definitive intensity-modulated radiation therapy for patients with head and neck cancer\u2020","volume":"65","author":"Hiraoka","year":"2024","journal-title":"J Radiat Res"},{"key":"2026100809072055800_ref5","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/01.PRS.0000131872.90767.50","article-title":"Chewing and swallowing after surgical treatment for oral cancer: functional evaluation in 196 selected cases","volume":"114","author":"Nicoletti","year":"2004","journal-title":"Plast Reconstr Surg"},{"key":"2026100809072055800_ref6","doi-asserted-by":"publisher","first-page":"3582","DOI":"10.1200\/JCO.2007.14.8841","article-title":"Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis","volume":"26","author":"Machtay","year":"2008","journal-title":"J Clin Oncol"},{"key":"2026100809072055800_ref7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa0912217","article-title":"Human papillomavirus and survival of patients with oropharyngeal cancer","volume":"363","author":"Ang","year":"2010","journal-title":"N Engl J Med"},{"key":"2026100809072055800_ref8","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1200\/JCO.20.03128","article-title":"Reduced-dose radiation therapy for HPV-associated oropharyngeal carcinoma (NRG oncology HN002)","volume":"39","author":"Yom","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026100809072055800_ref9","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.ijrobp.2015.08.033","article-title":"Phase 2 trial of de-intensified chemoradiation therapy for favorable-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma","volume":"93","author":"Chera","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026100809072055800_ref10","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1002\/cncr.31338","article-title":"Mature results of a prospective study of deintensified chemoradiotherapy for low-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma","volume":"124","author":"Chera","year":"2018","journal-title":"Cancer"},{"key":"2026100809072055800_ref11","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1200\/JCO.19.01007","article-title":"Phase II trial of de-intensified chemoradiotherapy for human papillomavirus-associated oropharyngeal squamous cell carcinoma","volume":"37","author":"Chera","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026100809072055800_ref12","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.ijrobp.2018.10.033","article-title":"Quality of life for patients with favorable-risk HPV-associated oropharyngeal cancer after de-intensified chemoradiotherapy","volume":"103","author":"Pearlstein","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026100809072055800_ref13","volume-title":"Paper presented at ASTRO 2024 Annual Meeting 2024","author":"Yom"},{"key":"2026100809072055800_ref14","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.radonc.2013.06.044","article-title":"Reduction of the dose to the elective neck in head and neck squamous cell carcinoma, a randomized clinical trial using intensity modulated radiotherapy (IMRT). Dosimetrical analysis and effect on acute toxicity","volume":"109","author":"Nuyts","year":"2013","journal-title":"Radiother Oncol"},{"key":"2026100809072055800_ref15","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.radonc.2016.08.009","article-title":"Reduction of the dose of radiotherapy to the elective neck in head and neck squamous cell carcinoma; a randomized clinical trial. Effect on late toxicity and tumor control","volume":"122","author":"Nevens","year":"2017","journal-title":"Radiother Oncol"},{"key":"2026100809072055800_ref16","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.radonc.2020.01.005","article-title":"Randomized clinical trial on reduction of radiotherapy dose to the elective neck in head and neck squamous cell carcinoma; update of the long-term tumor outcome","volume":"143","author":"Deschuymer","year":"2020","journal-title":"Radiother Oncol"},{"key":"2026100809072055800_ref17","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1200\/JCO-24-02194","article-title":"Clinical benefit and safety of reduced elective dose in definitive radiotherapy for head and neck squamous cell carcinoma: the UPGRADE-RT multicenter randomized controlled trial","volume":"43","author":"Bosch","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026100809072055800_ref18","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1200\/JCO-25-00928","article-title":"Caution needed before adopting reduced-dose elective neck irradiation in head and neck cancer: a response to UPGRADE-RT","volume":"43","author":"Kiyota","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026100809072055800_ref19","doi-asserted-by":"publisher","first-page":"S770","DOI":"10.1016\/j.annonc.2025.08.1954","article-title":"A phase III randomized trial of prophylactic radiation with 2-step40 versus SIB56 IMRT techniques for locally advanced squamous cell carcinoma of the head and neck (JCOG1912, NEW BRIDGE)","volume":"36","author":"Kodaira","year":"2026","journal-title":"Ann Oncol"},{"key":"2026100809072055800_ref20","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1158\/1078-0432.CCR-23-0334","article-title":"Efficacy and quality-of-life following involved nodal radiotherapy for head and neck squamous cell carcinoma: the INRT-AIR phase II clinical trial","volume":"29","author":"Sher","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026100809072055800_ref21","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/j.ijrobp.2024.08.022","article-title":"A phase II single arm trial of elective volume adjusted de-escalation radiotherapy (EVADER) in patients with low-risk HPV-related oropharyngeal squamous cell carcinoma","volume":"120","author":"Bratman","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026100809072055800_ref22","doi-asserted-by":"publisher","first-page":"S1221","DOI":"10.1016\/S0167-8140(24)01245-3","article-title":"691: a single-arm confirmatory trial of IMRT alone for early-stage oropharyngeal cancer: JCOG1208","volume":"194","author":"Nakamura","year":"2024","journal-title":"Radiother Oncol"},{"key":"2026100809072055800_ref23","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"key":"2026100809072055800_ref24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736(18)32752-1","article-title":"Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial","volume":"393","author":"Mehanna","year":"2019","journal-title":"Lancet"},{"key":"2026100809072055800_ref25","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(18)32779-X","article-title":"Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG oncology RTOG 1016): a randomised, multicentre, non-inferiority trial","volume":"393","author":"Gillison","year":"2019","journal-title":"Lancet"},{"key":"2026100809072055800_ref26","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.ijrobp.2021.04.015","article-title":"Randomized trial of radiation therapy with weekly cisplatin or cetuximab in low-risk HPV-associated oropharyngeal cancer (TROG 12.01) - a trans-Tasman radiation oncology group study","volume":"111","author":"Rischin","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026100809072055800_ref27","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1200\/JCO.20.02072","article-title":"ARTSCAN III: a randomized phase III study comparing chemoradiotherapy with cisplatin versus cetuximab in patients with locoregionally advanced head and neck squamous cell cancer","volume":"39","author":"Gebre-Medhin","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026100809072055800_ref28","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1200\/JCO.21.01293","article-title":"Weekly cisplatin plus radiation for postoperative head and neck cancer (JCOG1008): a multicenter, noninferiority, phase II\/III randomized controlled trial","volume":"40","author":"Kiyota","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026100809072055800_ref29","doi-asserted-by":"publisher","first-page":"6004","DOI":"10.1200\/JCO.2022.40.16_suppl.6004","article-title":"An open-non-inferiorityriority phase III RCT of weekly versus three weekly cisplatin and radical radiotherapy in locally advanced head and neck squamous cell carcinoma (ConCERT trial)","volume":"40","author":"Sharma","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026100809072055800_ref30","volume-title":"Presented at: 2026 Multidisciplinary Head and Neck Cancers Symposium","author":"Harari","year":"2026"},{"key":"2026100809072055800_ref31","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1200\/JCO.2017.74.9457","article-title":"Once-a-week versus once-every-3-weeks cisplatin chemoradiation for locally advanced head and neck cancer: a phase III randomized noninferiority trial","volume":"36","author":"Noronha","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026100809072055800_ref32","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.ijrobp.2010.06.038","article-title":"Phase III study of radiation therapy with or without cis-platinum in patients with unresectable squamous or undifferentiated carcinoma of the head and neck: an intergroup trial of the eastern cooperative oncology group (E2382)","volume":"81","author":"Quon","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026100809072055800_ref33","doi-asserted-by":"publisher","first-page":"3858","DOI":"10.1200\/JCO.2014.55.3925","article-title":"Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the radiation therapy oncology group 0129 trial: long-term report of efficacy and toxicity","volume":"32","author":"Nguyen-Tan","year":"2014","journal-title":"J Clin Oncol"},{"key":"2026100809072055800_ref34","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1200\/JCO.2003.01.008","article-title":"An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer","volume":"21","author":"Adelstein","year":"2003","journal-title":"J Clin Oncol"},{"key":"2026100809072055800_ref35","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1002\/(SICI)1097-0142(20000215)88:4&lt;876::AID-CNCR19&gt;3.0.CO;2-Y","article-title":"Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck","volume":"88","author":"Adelstein","year":"2000","journal-title":"Cancer"},{"key":"2026100809072055800_ref36","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1001\/jamaoto.2025.0848","article-title":"A proposal for HPV-associated oropharyngeal carcinoma in the ninth edition clinical TNM classification","volume":"151","author":"Huang","year":"2025","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"2026100809072055800_ref37","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.prro.2024.05.007","article-title":"Radiation therapy for HPV-positive oropharyngeal squamous cell carcinoma: an ASTRO clinical practice guideline","volume":"14","author":"Margalit","year":"2024","journal-title":"Pract Radiat Oncol"},{"key":"2026100809072055800_ref38","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1200\/JCO.2016.68.3300","article-title":"E1308: phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx- ECOG-ACRIN cancer research group","volume":"35","author":"Marur","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026100809072055800_ref39","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1093\/annonc\/mdy522","article-title":"OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer","volume":"30","author":"Seiwert","year":"2019","journal-title":"Ann Oncol"},{"key":"2026100809072055800_ref40","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.ijrobp.2020.04.014","article-title":"Dose and volume de-escalation for human papillomavirus-positive oropharyngeal cancer is associated with favorable posttreatment functional outcomes","volume":"107","author":"Foster","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026100809072055800_ref41","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S1470-2045(17)30246-2","article-title":"Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study","volume":"18","author":"Chen","year":"2017","journal-title":"Lancet Oncol"},{"key":"2026100809072055800_ref42","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1001\/jamaoncol.2024.1530","article-title":"Neoadjuvant Nivolumab plus chemotherapy followed by response-adaptive therapy for HPV+ oropharyngeal cancer: OPTIMA II phase 2 open-label nonrandomized controlled trial","volume":"10","author":"Rosenberg","year":"2024","journal-title":"JAMA Oncol"},{"key":"2026100809072055800_ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2026.107858","article-title":"Long-term outcomes of induction chemotherapy-guided reduced-dose chemoradiotherapy in poor-risk HPV-positive oropharyngeal cancer: results from the sequential quarterback trials","volume":"174","author":"Lovett","year":"2026","journal-title":"Oral Oncol"},{"key":"2026100809072055800_ref44","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1200\/JCO.23.01308","article-title":"Hypoxia-directed treatment of human papillomavirus-related oropharyngeal carcinoma","volume":"42","author":"Lee","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026100809072055800_ref45","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1158\/1078-0432.CCR-25-2820","article-title":"FDG-PET-based selective Deescalation of Chemoradiation in human papillomavirus-related oropharyngeal squamous cell carcinoma: a Multicenter phase II trial","volume":"32","author":"Mierzwa","year":"2026","journal-title":"Clin Cancer Res"},{"key":"2026100809072055800_ref46","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/S1470-2045(19)30410-3","article-title":"Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial","volume":"20","author":"Nichols","year":"2019","journal-title":"Lancet Oncol"},{"key":"2026100809072055800_ref47","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1200\/JCO.21.01961","article-title":"Randomized trial of radiotherapy versus transoral robotic surgery for oropharyngeal squamous cell carcinoma: long-term results of the ORATOR trial","volume":"40","author":"Nichols","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026100809072055800_ref48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaoncol.2022.0615","article-title":"Assessment of toxic effects and survival in treatment deescalation with radiotherapy vs transoral surgery for HPV-associated oropharyngeal squamous cell carcinoma: the ORATOR2 phase 2 randomized clinical trial","volume":"8","author":"Palma","year":"2022","journal-title":"JAMA Oncol"},{"key":"2026100809072055800_ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115343","article-title":"Radiation vs. trans-oral surgery for treatment de-escalation in HPV-related oropharyngeal cancers: primary analysis of the ORATOR2 randomized trial","volume":"220","author":"Palma","year":"2025","journal-title":"Eur J Cancer"},{"key":"2026100809072055800_ref50","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1200\/JCO.21.01752","article-title":"Phase II randomized trial of transoral surgery and low-dose intensity modulated radiation therapy in resectable p16+ locally advanced oropharynx cancer: an ECOG-ACRIN cancer research group trial (E3311)","volume":"40","author":"Ferris","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026100809072055800_ref51","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1200\/JCO-24-02550","article-title":"Long-term follow-up of E3311, an ECOG-ACRIN cancer research group phase II trial of transoral surgery and risk-based adjuvant treatment in human papillomavirus-initiated oropharynx cancer","volume":"43","author":"Burtness","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026100809072055800_ref52","doi-asserted-by":"publisher","DOI":"10.1200\/OA-25-00092","article-title":"Functional impact of transoral surgery and risk-based adjuvant therapy in human papillomavirus\u2013associated oropharyngeal cancer: swallowing outcomes from ECOG-ACRIN E3311","volume":"2","author":"Hutcheson","year":"2025","journal-title":"JCO Oncol Adv"},{"key":"2026100809072055800_ref53","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1200\/JCO.19.00463","article-title":"Phase II evaluation of aggressive dose De-escalation for adjuvant Chemoradiotherapy in human papillomavirus-associated oropharynx squamous cell carcinoma","volume":"37","author":"Ma","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026100809072055800_ref54","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.ijrobp.2022.05.047","article-title":"Long-term toxic effects, swallow function, and quality of life on MC1273: a phase 2 study of dose De-escalation for adjuvant Chemoradiation in human papillomavirus-positive oropharyngeal cancer","volume":"114","author":"Price","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026100809072055800_ref55","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S1470-2045(25)00324-9","article-title":"De-escalated adjuvant radiotherapy versus standard adjuvant treatment for human papillomavirus-associated oropharyngeal squamous cell carcinoma (MC1675): a phase 3, open-label, randomised controlled trial","volume":"26","author":"Ma","year":"2025","journal-title":"Lancet Oncol"},{"key":"2026100809072055800_ref56","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.ijrobp.2019.11.021","article-title":"A phase 2 trial of alternative volumes of oropharyngeal irradiation for De-intensification (AVOID): omission of the resected primary tumor bed after Transoral robotic surgery for human papilloma virus-related squamous cell carcinoma of the oropharynx","volume":"106","author":"Swisher-McClure","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026100809072055800_ref57","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.109773","article-title":"Circulating tumour HPV16 DNA quantification - a prognostic tool for progression-free survival in patients with HPV-related oropharyngeal carcinoma receiving curative chemoradiotherapy","volume":"186","author":"Adrian","year":"2023","journal-title":"Radiother Oncol"},{"key":"2026100809072055800_ref58","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00494","article-title":"Clearance profile of circulating tumor human papillomavirus DNA during radiotherapy predicts clinical outcomes in human papillomavirus-related oropharyngeal cancer","volume":"7","author":"Tanaka","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"2026100809072055800_ref59","doi-asserted-by":"publisher","first-page":"4682","DOI":"10.1158\/1078-0432.CCR-19-0211","article-title":"Rapid clearance profile of plasma circulating tumor HPV type 16 DNA during Chemoradiotherapy correlates with disease control in HPV-associated oropharyngeal cancer","volume":"25","author":"Chera","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2026100809072055800_ref60","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1158\/1078-0432.CCR-21-2338","article-title":"Early HPV ctDNA kinetics and imaging biomarkers predict therapeutic response in p16+ oropharyngeal squamous cell carcinoma","volume":"28","author":"Cao","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026100809072055800_ref61","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1186\/s12885-015-1598-x","article-title":"PATHOS: a phase II\/III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for human papillomavirus (HPV) positive oropharyngeal cancer","volume":"15","author":"Owadally","year":"2015","journal-title":"BMC Cancer"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/10\/1167\/68570371\/hyag096.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/10\/1167\/68570371\/hyag096.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:07:29Z","timestamp":1791464849000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/56\/10\/1167\/8713072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":61,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,6,22]]},"published-print":{"date-parts":[[2026,10,8]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyag096","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,6,22]]}}}